Drug Class Detail

Drug Class CXCR4 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
X4P-001 Mavorixafor X4P-001-IO|AMD-070|AMD-11070|AMD11070 CXCR4 Inhibitor 14 X4P-001, is a CXCR4 antagonist, which blocks the binding of CXCL12 to prevent metastasis and may activate cytotoxic T-lymphocytes (PMID: 23538388).
MSX-122 CXCR4 Inhibitor 14 MSX-122 is a CXCR4 antagonist, which inhibits SDF-1(CXCL12)-CXCR4 mediated signaling and may inhibit tumor cell metastasis (PMID: 22485156).
GMI-1359 CXCR4 Inhibitor 14 GMI-1359 is a dual inhibitor of Cxcr4 and E-selectin, which may inhibit leukemia cell adhesion and lead to apoptosis (Blood 2015 126(23):3790).
BKT140 TN14003|BL-8040|BL8040 CXCR4 Inhibitor 14 BKT140 is a selective CXCR4 antagonist that prevents SDF-1 (CXCL12) binding, which may lead to decreased tumor growth (PMID: 21138752).
SJA5 CXCR4 Inhibitor 14 SJA5 is a CXCR4 antagonist, which binds to and inhibits CXCR4, potentially resulting in decreased tumor cell migration (PMID: 25775124).
PF-06747143 CXCR4 Inhibitor 14 PF-06747143 is a CXCR4 antagonist, which inhibits CXCR4 and CXCL12-mediated cell signaling, potentially resulting in cell death and inhibition of tumor cell metastasis (PMID: 28526063).
POL5551 CXCR4 Inhibitor 14 POL5551 is an antagonist of CXCR4, which may lead to decreased tumor cell migration and increased sensitivity to chemotherapeutic agents (PMID: 26269605).
LY2510924 CXCR4 Inhibitor 14 LY2510924 is a selective CXCR4 antagonist that prevents SDF-1 binding, potentially resulting in decreased tumor cell migration (PMID: 25504752).
ALX-0651 CXCR4 Inhibitor 14 ALX-0651 is a nanobody that targets CXCR4 and prevents SDF-1 (CXCL12) binding, potentially resulting in decreased cell migration (PMID: 23211868)
Ulocuplumab BMS-936564|MDX1338 CXCR4 Inhibitor 14 Ulocuplumab (BMS-936564) is a monoclonal antibody that binds to CXCR4 and prevents binding of SDF-1 (CXCL12), potentially resulting in increased apoptosis and decreased migration of tumor cells (PMID: 23213054).
PRX177561 CXCR4 Inhibitor 14 PRX177561 is a CXCR4 antagonist, which may decrease tumor growth in combination with other agents (PMID: 28057017).
TG-0054 CXCR4 Inhibitor 14 TG-0054 binds to CXCR4 and inhibits SDF-1 (CXCL12) binding, potentially resulting in increased mobilization of hematopoietic cells (NCI Drug Dictionary).
POL6326 Balixafortide CXCR4 Inhibitor 14 POL6326 binds to CXCR4 and inhibits SDF-1 (CXCL12) binding, potentially resulting in increased mobilization of hematopoietic cells (NCI Drug Dictionary).
Plerixafor Mozobil AMD3100 CXCR4 Inhibitor 14 Mozobil (plerixafor) inhibits CXCR4 and CXCL12-mediated cell signaling to influence tumor metastasis (PMID: 19641136, PMID: 16815309).
Molecular Profile Protein Effect Treatment Approaches